Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Overweight | Cantor Fitzgerald | |
| 7/20/2022 | $16.00 | Neutral | Goldman |
| 2/23/2022 | $10.00 → $12.00 | Underweight | Morgan Stanley |
| 2/11/2022 | $28.00 | Buy | EF Hutton |
Cantor Fitzgerald initiated coverage of Innoviva with a rating of Overweight
Goldman initiated coverage of Innoviva with a rating of Neutral and set a new price target of $16.00
Morgan Stanley reiterated coverage of Innoviva with a rating of Underweight and set a new price target of $12.00 from $10.00 previously
Cantor Fitzgerald analyst Louise Chen reiterates Innoviva (NASDAQ:INVA) with a Overweight.
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes. Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The analyst says Breo and Anoro have exceeded expectations, even during challenging times such a
Cantor Fitzgerald analyst Louise Chen initiates coverage on Innoviva (NASDAQ:INVA) with a Overweight rating.
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Format: Corporate Presentation Date: Tuesday, September 10, 2024 Time: 10:30 a.m. Eastern Time 2024 Cantor Fitzgerald Global Healthcare Conference Format: Fireside chat Date: Wednesday, September 18, 2024 Time: 3:40 p.m. Eastern Time
Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million Important treatment guidelines and guidance updates recognized our key products: XACDURO® by 2024 Infectious Diseases Society of America (IDSA); XERAVA® by 2024 Surgical Infection Society XACDURO® approved in China Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strateg
10-Q - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
10-Q - Innoviva, Inc. (0001080014) (Filer)
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the
Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million Important treatment guidelines and guidance updates recognized our key products: XACDURO® by 2024 Infectious Diseases Society of America (IDSA); XERAVA® by 2024 Surgical Infection Society XACDURO® approved in China Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strateg
Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core product GIAPREZA® Strong pipeline progress: positive Phase 3 zoliflodacin clinical trial results in uncomplicated gonorrhea highlighted at ESCMID Global 2024; on track to submit NDA in early 2025 Derek Small appointed to the Company's Board of Directors Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
SC 13G - Innoviva, Inc. (0001080014) (Subject)
SC 13D - Innoviva, Inc. (0001080014) (Subject)
SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v